Premium
1,25‐Dihydroxyvitamin D 3 increases type 1 interleukin‐1 receptor expression in a murine T cell line
Author(s) -
Lacey D. L.,
Erdmann J. M.,
Tan H.L.
Publication year - 1993
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240520208
Subject(s) - receptor , calcitriol receptor , interleukin 1 receptor , interleukin 2 , metabolite , cytokine , vitamin d and neurology , medicine , interleukin , endocrinology , chemistry , biology , microbiology and biotechnology , biochemistry
The biologically active metabolite of vitamin D 3 , 1,25 (OH) 2 D 3 , exerts important immunoregulatory effects in addition to being a central mediator of calcium/phosphate metabolism. Utilizing an interleukin 1 responsive murine T cell line and 125 I‐interleukin 1α, we show that 1,25 (OH) 2 D 3 (5,50 nM) enhanced 125 I‐interleukin 1α binding up to almost 2‐fold over control. This 1,25 (OH) 2 D 3 effect occurred in a dose‐dependent manner and was detectable after 24 h but not before 7 h of culture. Scatchard analysis of 125 I‐interleukin 1α binding data demonstrated that 1,25 (OH) 2 D 3 enhanced interleukin 1 receptor number without a significant change in affinity. The biologically less potent metabolite of vitamin D 3 , 25 (OH) D 3 , also augmented 125 I‐interleukin 1α binding but at steroid levels 2–3 log orders greater than 1,25 (OH) 2 D 3 . This observation, combined with the presence of high‐affinity 3 H‐1,25 (OH) 2 D 3 receptors (88 sites/cell, K = 0.45 nM) in cytosolic extracts, strongly suggests that the nuclear vitamin D receptor mediates this steroid's effect on interleukin 1 receptor expression. Based on the capacity of an anti‐type 1 interleukin 1 receptor monoclonal antibody (35F5) to block 1,25 (OH) 2 D 3 ‐enhanced 125 I‐interleukin 1α binding, we conclude that this steroid augments type 1 interleukin 1 receptor expression. When combined with interleukin 1, a cytokine that also impacts MD10 interleukin 1 receptor expression, 1,25 (OH) 2 D 3 enhanced interleukin 1 receptor expression. Northern blots hybridized with a 32 P‐type 1 interleukin 1 receptor cDNA probe show that 1,25 (OH) 2 D 3 enhanced type 1 interleukin 1 receptor steady state mRNA levels. Functionally, 1,25 (OH) 2 D 3 pretreatment augmented the MD10 proliferative response to suboptimal levels of interleukin 1 (< 100 fM interleukin 1α). These findings further support 1,25 (OH) 2 D 3 's role as an immunoregulatory molecule and provides a possible mechanism by which this steroid could potentiate certain immune activities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom